Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 584 clinical trials
Heterogeneously Hypofractionated Radiotherapy for Locally Advanced NSCLC

The options for patients with locally advanced non-small cell lung cancer (NSCLC) who are not candidates for a standard definitive chemoradiotherapy regime are meagre. These are patients who are not fit for a chemoradiotherapy schedule of 66 Gy in 2 Gy fractions due to either tumour extent, resulting in excessive …

  • 0 views
  • 04 Oct, 2022
  • 1 location
GD2 Specific CAR and Interleukin-15 Expressing Autologous NKT Cells to Treat Children With Neuroblastoma (GINAKIT2)

This research study combines two different ways of fighting cancer: antibodies and Natural Killer T cells (NKT). Antibodies are types of proteins that protect the body from infectious diseases and possibly cancer. T cells, also called T lymphocytes, are special white blood cells that can kill other cells, including cells …

14g2a
tumor cells
fludarabine
platelet count
cyclophosphamide
  • 42 views
  • 04 Oct, 2022
  • 1 location
Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients. (FIL_COLUMN)

This is a prospective, phase 2, multicenter, open-label, single-arm study. Primary objective is to assess the efficacy of loncastuximab tesirine given as consolidation therapy after salvage immunochemotherapy in BTKi (Bruton Tyrosine Kinase inhibitors) -treated (or BTKi intolerant) R/R (Relapse or Refractory) MCL (Mantle Cell Lymphoma) patients. The sponsor of this …

  • 0 views
  • 15 May, 2022
  • 1 location
Phase I Study of Autologous T Lymphocytes Expressing GD2-specific Chimeric Antigen and Constitutively Active IL-7 Receptors for the Treatment of Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Solid Cancers(GAIL-N)

This study is for patients with neuroblastoma, sarcoma, uveal melanoma, breast cancer, or another cancer that expresses a substance on the cancer cells called GD2. The cancer has either come back after treatment or did not respond to treatment. Because there is no standard treatment at this time, patients are …

liver disease
tumor cells
platelet count
refractory osteosarcoma
refractory neuroblastoma
  • 34 views
  • 22 Sep, 2022
  • 2 locations
68Ga-PSMA-617 PET/CT for PSMA-expressing Tumor: a Pragmatic Study

This project aims to monitor the innocuity/safety profile of cyclotron-produced [68Ga]-PSMA-617 PET imaging in PSMA-expressing cancers. It is a single-site, pragmatic, non-randomized and open-label study, with no control group. Although prostate cancers constitute the usual recommended population for this PET modality, recent evidences suggest that most solid tumors express substantial …

  • 0 views
  • 19 Apr, 2022
  • 1 location
FDG an Myocardial Infarction: The PIAF Trial

will be included in this international multicenter trial. Non-enhanced whole-body FDG PET/CT will be performed in all patients and the arterial FDG uptake in the carotid arteries as well as the aorta

  • 0 views
  • 10 Dec, 2021
Vascular Graft Infections

techniques (PET/CT and MRI) for the diagnosis of PVGI, and their individual role for the assessment of treatment response. Thirdly, investigators will evaluate the bacterial diversity of vascular wound

  • 0 views
  • 21 Jan, 2021
  • 1 location
Microglial Cells Activation Imaging Using PET-CT With 18F-DPA714

labels microglial cells. The investigators aim to explore the clinical feasibility used PET-CT with 18F-DPA714 to monitor microglial cells activation of brain in several different disease. This study

Accepts healthy volunteers
  • 0 views
  • 18 Feb, 2022
  • 2 locations
Head-to-head Comparison Between [18F]-FDG PET/CT and PET/MRI in Lymphomas

Investigating the performance of 18F-FDG PET/CT and PET/MRI in lymphomas

  • 0 views
  • 09 Jun, 2022
  • 1 location
USE OF 18FDG PET-CT TO PREDICT THE RESPONSE OF MANDIBULAR OSTEORADIONECROSIS TO THE PENTOCLO PROTOCOL WITH DOCUMENTED ANTIBIOTHERAPY

This study is created in order to refine and reduce the duration between the medical and surgical therapeutic sequences (when the surgery is necessary) in these fragile patients knowing that conventional radiological changes can only be observed with a delay comprised between 3 and 6 months starting from observed clinical …

  • 0 views
  • 10 Apr, 2021
  • 1 location